# ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

> **NCT04236219** · PHASE1 · COMPLETED · sponsor: **Allena Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** ALLN-346
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04236219
- **Lead sponsor:** Allena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-02
- **Primary completion:** 2020-11-06
- **Final completion:** 2020-11-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236219, "ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04236219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*